Cytek Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Cytek Biosciences
CTKB Stock  USD 4.48  0.08  1.82%   
Cytek Biosciences' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Cytek Biosciences' valuation are provided below:
Gross Profit
104.5 M
Profit Margin
(0.33)
Market Capitalization
572.8 M
Enterprise Value Revenue
1.7132
Revenue
201.5 M
We have found one hundred twenty available fundamental signals for Cytek Biosciences, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of Cytek Biosciences prevailing market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. As of March 2, 2026, Market Cap is expected to decline to about 704.8 M. In addition to that, Enterprise Value is expected to decline to about 620.9 M

Cytek Biosciences Total Revenue

163.06 Million

Check Cytek Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cytek Biosciences' main balance sheet or income statement drivers, such as Tax Provision of 386.4 K, Net Interest Income of 12.5 M or Interest Income of 12.5 M, as well as many indicators such as Price To Sales Ratio of 3.04, Dividend Yield of 0.0 or PTB Ratio of 1.98. Cytek financial statements analysis is a perfect complement when working with Cytek Biosciences Valuation or Volatility modules.
  
Build AI portfolio with Cytek Stock
Check out the analysis of Cytek Biosciences Correlation against competitors.
For information on how to trade Cytek Stock refer to our How to Trade Cytek Stock guide.

Cytek Biosciences Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets428.8 M461.5 M223 M
Slightly volatile
Other Current Liabilities26 M42.9 M19 M
Slightly volatile
Total Current Liabilities52.1 M77.8 M33.7 M
Slightly volatile
Other Liabilities23.8 M34.9 M20.8 M
Slightly volatile
Property Plant And Equipment Net19.4 M29.3 M8.9 M
Slightly volatile
Current Deferred Revenue17 M28.5 M9.2 M
Slightly volatile
Accounts Payable4.4 M6.4 M3.2 M
Slightly volatile
Cash138.7 M90.9 M95.5 M
Slightly volatile
Non Current Assets Total60.7 M69.5 M27.6 M
Slightly volatile
Non Currrent Assets Other7 M6.7 M1.9 M
Slightly volatile
Other Assets1.091.152.9 M
Pretty Stable
Cash And Short Term Investments267.6 M261.5 M131.9 M
Slightly volatile
Net Receivables46.4 M62.5 M29.5 M
Slightly volatile
Good Will11.1 M16.7 M5.1 M
Slightly volatile
Common Stock Total Equity83.9 K155.2 K59 K
Slightly volatile
Common Stock Shares Outstanding106.5 M127.7 M131.5 M
Slightly volatile
Liabilities And Stockholders Equity428.8 M461.5 M223 M
Slightly volatile
Non Current Liabilities Total56.4 M42 M80.5 M
Slightly volatile
Inventory43.2 M48.4 M28.5 M
Slightly volatile
Other Current Assets10.9 M19.5 M5.5 M
Slightly volatile
Other Stockholder Equity340.8 M441.1 M147.9 M
Slightly volatile
Total Liabilities94.3 M119.8 M113.4 M
Very volatile
Property Plant And Equipment Gross44.5 M42.4 M12.2 M
Slightly volatile
Total Current Assets368.1 M392 M195.3 M
Slightly volatile
Capital Stock103.6 K148.3 K59.2 K
Slightly volatile
Non Current Liabilities Other18.5 M13.1 M15.5 M
Pretty Stable
Net Working Capital311.4 M378.1 M165.2 M
Slightly volatile
Short Term Debt5.4 M7.6 M6.9 M
Pretty Stable
Intangible Assets10.9 M16.8 M4.9 M
Slightly volatile
Common Stock109.1 K148.3 K59.5 K
Slightly volatile
Property Plant Equipment16.5 M15.7 M5.4 M
Slightly volatile
Short and Long Term Debt Total14.5 M14 M7.4 M
Slightly volatile
Short and Long Term Debt5.6 M5.4 M2.8 M
Pretty Stable
Capital Surpluse476.6 M509.3 M435.2 M
Slightly volatile
Deferred Long Term Liabilities12.6 M15.1 M10.9 M
Slightly volatile
Long Term Debt1.3 M945 K2 M
Slightly volatile
Long Term Debt Total1.8 M2 M2.2 M
Slightly volatile

Cytek Biosciences Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Income12.5 M11.9 M3.2 M
Slightly volatile
Depreciation And Amortization6.2 M12 M2.9 M
Slightly volatile
Interest Expense450.3 K474 K758.3 K
Slightly volatile
Selling General Administrative34.2 M58.9 M18.4 M
Slightly volatile
Selling And Marketing Expenses36.3 M49.4 M21.1 M
Slightly volatile
Total Revenue163.1 M201.5 M101.3 M
Slightly volatile
Gross Profit92 M104.5 M55 M
Slightly volatile
Other Operating Expenses176.4 M241.9 M116.2 M
Slightly volatile
Research Development31.7 M36.5 M18.5 M
Slightly volatile
Cost Of Revenue71.1 M97 M46.2 M
Slightly volatile
Total Operating Expenses105.4 M144.8 M70 M
Slightly volatile
Reconciled Depreciation12.7 M12.1 M3.2 M
Slightly volatile
Non Operating Income Net Other6.8 M6.5 M1.8 M
Slightly volatile

Cytek Biosciences Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation15.3 M24.6 M6.8 M
Slightly volatile
Begin Period Cash Flow184.2 M98.7 M103.7 M
Slightly volatile
Depreciation6.2 M12 M2.9 M
Slightly volatile
Capital Expenditures4.6 M4.1 M2.5 M
Slightly volatile
End Period Cash Flow139.2 M90.9 M96 M
Slightly volatile
Change To Netincome21 M20 M7 M
Slightly volatile
Dividends Paid922.4 K1.7 M486.1 K
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio3.043.201729.4237
Slightly volatile
Days Sales Outstanding81.2113106
Slightly volatile
Stock Based Compensation To Revenue0.0610.1220.0375
Slightly volatile
Capex To Depreciation0.320.3412.4019
Slightly volatile
EV To Sales2.682.820528.6329
Slightly volatile
Inventory Turnover1.332.00371.6001
Pretty Stable
Days Of Inventory On Hand248182230
Very volatile
Payables Turnover13.0915.137814.1092
Slightly volatile
Sales General And Administrative To Revenue0.150.29250.1485
Slightly volatile
Research And Ddevelopement To Revenue0.150.1810.1677
Slightly volatile
Capex To Revenue0.02180.02030.0214
Slightly volatile
Cash Per Share1.472.04730.962
Slightly volatile
Days Payables Outstanding26.0624.111926.7815
Slightly volatile
Intangibles To Total Assets0.07630.07260.0277
Slightly volatile
Current Ratio8.055.03825.1918
Slightly volatile
Receivables Turnover4.073.22343.4899
Slightly volatile
Capex Per Share0.02510.0320.0183
Slightly volatile
Revenue Per Share0.91.57730.745
Slightly volatile
Interest Debt Per Share0.06330.11360.0363
Slightly volatile
Debt To Assets0.02250.03040.0191
Slightly volatile
Graham Number1.321.341.2352
Very volatile
Operating Cycle360295337
Pretty Stable
Days Of Payables Outstanding26.0624.111926.7815
Slightly volatile
Long Term Debt To Capitalization0.04140.03950.0092
Slightly volatile
Quick Ratio7.14.41584.3163
Slightly volatile
Net Income Per E B T2.342.22981.213
Slightly volatile
Cash Ratio1.111.16772.6055
Slightly volatile
Cash Conversion Cycle334271310
Very volatile
Days Of Inventory Outstanding248182230
Very volatile
Days Of Sales Outstanding81.2113106
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.971.87151.074
Pretty Stable
Fixed Asset Turnover6.536.871338.4917
Slightly volatile
Debt Ratio0.02250.03040.0191
Slightly volatile
Price Sales Ratio3.043.201729.4237
Slightly volatile
Asset Turnover0.480.43660.644
Slightly volatile
Gross Profit Margin0.450.51840.5197
Slightly volatile

Cytek Biosciences Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap704.8 M741.9 M2 B
Slightly volatile
Enterprise Value620.9 M653.6 M1.9 B
Slightly volatile

Cytek Fundamental Market Drivers

Forward Price Earnings370.3704
Cash And Short Term Investments261.5 M

Cytek Upcoming Events

27th of February 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Cytek Biosciences Financial Statements

Cytek Biosciences stakeholders use historical fundamental indicators, such as Cytek Biosciences' revenue or net income, to determine how well the company is positioned to perform in the future. Although Cytek Biosciences investors may analyze each financial statement separately, they are all interrelated. For example, changes in Cytek Biosciences' assets and liabilities are reflected in the revenues and expenses on Cytek Biosciences' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Cytek Biosciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue28.5 M17 M
Total Revenue201.5 M163.1 M
Cost Of Revenue97 M71.1 M
Stock Based Compensation To Revenue 0.12  0.06 
Sales General And Administrative To Revenue 0.29  0.15 
Research And Ddevelopement To Revenue 0.18  0.15 
Capex To Revenue 0.02  0.02 
Revenue Per Share 1.58  0.90 
Ebit Per Revenue(0.20)(0.19)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
FSLYFastly Class A
MOBMobilicom Limited American
CMGChipotle Mexican Grill
When determining whether Cytek Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cytek Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cytek Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cytek Biosciences Stock:
How To Invest In Cytek
Details
Is Cytek Stock a good investment?
Details
What is Cytek Biosciences' Net Worth?
Details
Largest Health Care Equipment & Supplies Companies
View
Largest Health Care Equipment & Services Companies
View
Check out the analysis of Cytek Biosciences Correlation against competitors.
For information on how to trade Cytek Stock refer to our How to Trade Cytek Stock guide.
You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytek Biosciences. Projected growth potential of Cytek fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Cytek Biosciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth
0.735
Earnings Share
(0.11)
Revenue Per Share
1.577
Quarterly Revenue Growth
0.081
Return On Assets
(0.05)
Investors evaluate Cytek Biosciences using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Cytek Biosciences' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Cytek Biosciences' market price to deviate significantly from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
It's important to distinguish between Cytek Biosciences' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cytek Biosciences should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Cytek Biosciences' market price signifies the transaction level at which participants voluntarily complete trades.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY